GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Universal Biosensors Inc (ASX:UBI) » Definitions » Cash Ratio

Universal Biosensors (ASX:UBI) Cash Ratio : 1.83 (As of Dec. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Universal Biosensors Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Universal Biosensors's Cash Ratio for the quarter that ended in Dec. 2024 was 1.83.

Universal Biosensors has a Cash Ratio of 1.83. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Universal Biosensors's Cash Ratio or its related term are showing as below:

ASX:UBI' s Cash Ratio Range Over the Past 10 Years
Min: 0.89   Med: 2.31   Max: 3.43
Current: 1.83

During the past 13 years, Universal Biosensors's highest Cash Ratio was 3.43. The lowest was 0.89. And the median was 2.31.

ASX:UBI's Cash Ratio is ranked better than
63.08% of 856 companies
in the Medical Devices & Instruments industry
Industry Median: 1.1 vs ASX:UBI: 1.83

Universal Biosensors Cash Ratio Historical Data

The historical data trend for Universal Biosensors's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Biosensors Cash Ratio Chart

Universal Biosensors Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.63 1.63 1.99 1.72 1.83

Universal Biosensors Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 1.45 3.70 2.86 1.83

Competitive Comparison of Universal Biosensors's Cash Ratio

For the Medical Devices subindustry, Universal Biosensors's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Biosensors's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Universal Biosensors's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Universal Biosensors's Cash Ratio falls into.


;
;

Universal Biosensors Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Universal Biosensors's Cash Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash Ratio (A: Dec. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=8.544/4.661
=1.83

Universal Biosensors's Cash Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash Ratio (Q: Dec. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=8.544/4.661
=1.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Universal Biosensors  (ASX:UBI) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Universal Biosensors Cash Ratio Related Terms

Thank you for viewing the detailed overview of Universal Biosensors's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Biosensors Business Description

Traded in Other Exchanges
N/A
Address
1 Corporate Avenue, Rowville, VIC, AUS, 3178
Universal Biosensors Inc is biosensor company in electrochemical cell technology to develop a diverse range of biosensor test strips. The company's platform develops a diverse range of biosensor test strips used in conjunction with point-of-use devices that are used in various industries such as healthcare (point-of-care), wine, food and agriculture. It manufactures and distributes PT-INR coagulation test strips and devices, Xprecia, Stride and Xprecia Prime which are medical devices, Sentia non-medical wine testing products, and Petrackr which is a blood glucose test used in cats and dogs. It has one reportable segment: specialist biosensors company. Geographically, the company generates majority of its revenue from Australia and rest from Americas, Europe and other markets.

Universal Biosensors Headlines

No Headlines